Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHB4 | P54760 | 2/20 | 0.58 |
| ▸ | BRAF | P15056 | 16/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | BTK | Q06187 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6925932 | 0.87 | BTK (0.54) | EPHB4BRAFCYP3A4KDRBTK | |
| SCHEMBL10259364 | 0.83 | EPHB4 (0.61) | EPHB4BRAFCYP3A4KDRBTK | |
| SCHEMBL3530830 | 0.82 | EPHB4 (0.60) | EPHB4BRAFCYP3A4KDRBTK | |
| SCHEMBL6928473 | 0.80 | EPHB4 (0.58) | EPHB4BRAFCYP3A4KDR | |
| SCHEMBL3530501 | 0.79 | EPHB4 (0.69) | EPHB4BRAFCYP3A4KDRBTK | |
| SCHEMBL5109039 | 0.77 | EPHB4 (0.69) | EPHB4BRAFCYP3A4KDR | |
| SCHEMBL6927096 | 0.76 | EPHB4 (0.44) | EPHB4BRAFKDR | |
| SCHEMBL6927094 | 0.76 | BTK (0.56) | EPHB4CYP3A4KDRBTK | |
| SCHEMBL10198705 | 0.75 | KDR (0.57) | CYP3A4KDRBTK | |
| SCHEMBL6924755 | 0.72 | EPHB4 (0.35) | EPHB4CYP3A4KDRBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2549868-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2015-01-07 | — | — | EP | disclosed |
| US-20130018038-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2013-01-17 | — | — | US | disclosed |
| US-20130018038-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2013-01-17 | — | — | US | disclosed |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-03-29 | — | — | US | disclosed |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-03-29 | — | — | US | disclosed |
| WO-2011119663-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018038-A1 | CHEMICAL COMPOUNDS | BRCA1, IRS1, IGF1R | EPHB4 2288/4885BRAF 294/4885CYP3A4 1750/4885 |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | BRCA1, IRS1, IGF1R | EPHB4 2288/4885BRAF 294/4885CYP3A4 1750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.